Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 12:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Asthma, Allergic Clear all
Terminated Phase 2 Interventional

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

NCT03960606
View directory record Official record
Conditions
Allergic Bronchopulmonary Aspergillosis
Interventions
PUR1900, Placebo
Combination Product
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Denver, Colorado • New Haven, Connecticut • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 9, 2026, 12:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Evaluation of Ten Allergy Skin Prick Test Devices

NCT03509766
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Food Allergy, Skin Testing
Interventions
Histamine skin testing
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 9, 2026, 12:54 PM EDT
Recruiting No phase listed Observational

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

NCT02327897
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 9, 2026, 12:54 PM EDT
Terminated Phase 1 Interventional

Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma

NCT00630461
View directory record Official record
Conditions
Mild Allergic Rhinitis, Mild Allergic Rhinitis With Mild Asthma
Interventions
Clinical Center Reference Endotoxin
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Sep 9, 2026, 12:54 PM EDT
Completed Phase 4 Interventional

The Effect of Cetirizine on Bronchoconstriction

NCT03340740
View directory record Official record
Conditions
Allergic Rhinitis, Asthma
Interventions
Cetirizine Hydrochloride 1 MG/ML, Placebo - Concentrate
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
6 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 9, 2026, 12:54 PM EDT
Terminated Early Phase 1 Interventional Results available

Identification of Allergic Asthmatics Reactive to Felis Catus (Cat Hair) Allergen Inhalation

NCT03780387
View directory record Official record
Conditions
Asthma Atopic
Interventions
Felis Catus
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 9, 2026, 12:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Children's Respiratory and Environmental Workgroup

NCT03213184
View directory record Official record
Conditions
Asthma, Allergic Asthma, Allergies, Healthy
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
10
States / cities
Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 9, 2026, 12:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Biomarkers of Irritant-Induced and Allergic Asthma

NCT02740543
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate HFA 220
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 9, 2026, 12:54 PM EDT
Completed Phase 2 Interventional Results available

Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure

NCT02911688
View directory record Official record
Conditions
Allergic Asthma
Interventions
gamma tocopherol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 9, 2026, 12:54 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Viral Mucosal Reprogramming

NCT05331170
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Cat Allergy, Healthy
Interventions
Research Grade RG-RV
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 9, 2026, 12:54 PM EDT
Active, not recruiting Early Phase 1 Interventional

Vaginal Microbiome Exposure and Immune Responses in C-section Infants

NCT03567707
View directory record Official record
Conditions
Allergic Diseases, Asthma
Interventions
Vaginal seeding, Placebo Seeding, Standard care, Post-seeding Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 9, 2026, 12:54 PM EDT
Terminated Phase 2 Interventional

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

NCT01673672
View directory record Official record
Conditions
Moderate to Severe Allergic Asthma
Interventions
CYT003, Placebo
Biological
Lead sponsor
Cytos Biotechnology AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 9, 2026, 12:54 PM EDT
Completed No phase listed Observational

XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States

NCT05157087
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
16,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 9, 2026, 12:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Audio Data Collection for Identification and Classification of Coughing

NCT04326309
View directory record Official record
Conditions
COVID-19, Coronavirus Infections, Hay Fever, Asthma, Chronic Obstructive Pulmonary Disease, Influenza, Common Cold, Respiratory Tract Infections, Healthy
Interventions
Not listed
Lead sponsor
HealthMode Inc.
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 9, 2026, 12:54 PM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Asthma Inflammation Research

NCT01536522
View directory record Official record
Conditions
Asthma, Allergic Asthma, Non-allergic Asthma
Interventions
Nutritional approach for asthma, Low Caloric Shake, whole lung allergen challenge
Dietary Supplement · Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 9, 2026, 12:54 PM EDT
Completed Phase 1 Interventional

The Role of Vitamins E and C in Maintaining Lung Health in People With Asthma

NCT00142610
View directory record Official record
Conditions
Asthma
Interventions
Vitamin
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 9, 2026, 12:54 PM EDT
Completed Phase 3 Interventional Results available

Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.

NCT00500539
View directory record Official record
Conditions
Asthma
Interventions
omalizumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
12 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Palmdale, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Sep 9, 2026, 12:54 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers

NCT03567694
View directory record Official record
Conditions
Asthma
Interventions
HA115, Placebo
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 9, 2026, 12:54 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol for Patients With Eosinophilic Esophagitis

NCT05095116
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011 3 mg HS
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years and older
U.S. locations
35
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Camarillo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 9, 2026, 12:54 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

NCT00670930
View directory record Official record
Conditions
Allergic Asthma
Interventions
omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 9, 2026, 12:54 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

NCT01125748
View directory record Official record
Conditions
Allergic Asthma
Interventions
Omalizumab, Placebo, Asthma therapies
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
17 Years to 70 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
100
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 9, 2026, 12:54 PM EDT
Withdrawn Phase 2 Interventional

CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids

NCT02087644
View directory record Official record
Conditions
Asthma
Interventions
CYT003, Placebo
Biological
Lead sponsor
Cytos Biotechnology AG
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 9, 2026, 12:54 PM EDT
Not listed Not applicable Interventional

Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma

NCT00286416
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
omalizumab (Xolair)
Drug
Lead sponsor
Scripps Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2006 · Synced Sep 9, 2026, 12:54 PM EDT
Completed Phase 2 Interventional Results available

Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study

NCT00346398
View directory record Official record
Conditions
Asthma, Allergic Sensitization
Interventions
Oral mucosal immunoprophylaxis (OMIP), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 30 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Sep 9, 2026, 12:54 PM EDT